-- Scott Roberts
FRIDAY, Jan. 27 (HealthDay News) -- Bydureon (exenatide extended
release), Amylin Pharmaceuticals' long-acting version of the
diabetes drug Byetta, has been approved by the U.S. Food and Drug
The once-weekly injection will include a label warning that the
drug caused certain thyroid tumors in rats, the
Dow Jones news service reported. It's not known whether the
drug causes such tumors in people, the label warning says. But the
drug shouldn't be used by people with a family history of medullary
thyroid carcinoma (a form of cancer), the warning continues.
Twice in 2010, the FDA declined approval of Bydureon, requesting
additional studies and clinical information,
Dow Jones reported.
Bydureon is a "glucagon-like peptide-1 (GLP-1) receptor," a
class of medications that helps the body produce more insulin,
which helps regulate blood sugar.
Amylin is based in San Diego, Calif.
For more about
type 2 diabetes, visit MedlinePlus.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.